Out of SFA very small loss. (commisions)
In VVUS @ 4
The sky is limit for this one.
I sold this morning at 2 1/4 and just bought back
in a 4
A mistake but I will move on.
Check out the news on this baby.
Female Sexual Dysfunction Patent Granted to VIVUS; VIVUS Plans Diversification of R&D
MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 8, 1999--VIVUS, Inc. (Nasdaq:VVUS) has been issued patent no. 5877216 for the "Treatment of Female Sexual Dysfunction" by the U.S. Patent Office.
This patent provides VIVUS with broad protection for the commercialization of topical formulations of vasodilating agents and steroid hormones for the treatment of sexual dysfunctions effecting women. Therapeutic opportunities include treatments for women with arousal and orgasm dysfunction, the enhancement of vaginal lubrication, and the improvement of vaginal muscle tone.
"This important patent underscores VIVUS' commitment to diversify its research and development efforts within urology beyond the treatment of male erectile dysfunction," stated Leland Wilson, President and CEO of VIVUS, Inc.
Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra.
Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).
CONTACT:
VIVUS, Inc.
Nina W. Ferrari, 650/934-5200
IR@VIVUS.com |
